Work Packages
Research Work Packages
WP1: Efficient discovery of allosteric modulators.
WP Lead Beneficiary: Sosei Heptares Therapeutics Limited
The main objectives of WP1 are the identification of allosteric pockets and allosteric ligands.
WP Lead Beneficiary: Sosei Heptares Therapeutics Limited
The main objectives of WP1 are the identification of allosteric pockets and allosteric ligands.
ESRs involved:
ESR1, ESR2, ESR3, ESR4, ESR6, ESR7, ESR8, ESR9, ESR11, ESR13, ESR14
ESR1, ESR2, ESR3, ESR4, ESR6, ESR7, ESR8, ESR9, ESR11, ESR13, ESR14
WP2: Understanding allosteric response
WP Lead Beneficiary: University of Vienna
The main objectives of WP2 are to investigate allostery at the molecular level as well as to study the biological response of allosteric ligands.
WP Lead Beneficiary: University of Vienna
The main objectives of WP2 are to investigate allostery at the molecular level as well as to study the biological response of allosteric ligands.
ESRs involved:
ESR1, ESR2, ESR3, ESR4, ESR5, ESR6, ESR7, ESR8, ESR9, ESR10, ESR12, ESR14
ESR1, ESR2, ESR3, ESR4, ESR5, ESR6, ESR7, ESR8, ESR9, ESR10, ESR12, ESR14
WP3: Platform development to uncover allosteric ligand function
WP Lead Beneficiary: University of Barcelona
The main objectives of WP3 are the development of a theoretical framework for allosteric modulation as well as a platform for the discovery of allosteric drugs.
WP Lead Beneficiary: University of Barcelona
The main objectives of WP3 are the development of a theoretical framework for allosteric modulation as well as a platform for the discovery of allosteric drugs.
ESRs involved:
ESR1, ESR2, ESR3, ESR4, ESR6, ESR7, ESR8, ESR9, ESR10, ESR11, ESR12, ESR13, ESR14
ESR1, ESR2, ESR3, ESR4, ESR6, ESR7, ESR8, ESR9, ESR10, ESR11, ESR12, ESR13, ESR14
Non-Scientific Work Packages
WP4: Training
WP Lead Beneficiary: Forschungszentrum Jülich
ALLODD aims at creating a new generation of young scientists with a broad understanding and skill set in allostery in drug discovery. All training objectives and activities are tailored to ALLODD to support the ESRs future career.
WP Lead Beneficiary: Forschungszentrum Jülich
ALLODD aims at creating a new generation of young scientists with a broad understanding and skill set in allostery in drug discovery. All training objectives and activities are tailored to ALLODD to support the ESRs future career.
WP5: Dissemination, Exploitation and Communication
WP Lead Beneficiary: University of Strasbourg
In ALLODD, all ESRs are actively involved in bringing the project, the objectives and results of ALLODD closer to the research community, relevant industry and public stakeholders, schools, wider public and press.
Our activities include public engagement activities for the non-scientific community, as well as the dissemination of project results through publications and presentations for the scientific community and industry.
WP5 also aims to ensure appropriate and efficient exploitation of the intellectual property emanating from the project results.
WP Lead Beneficiary: University of Strasbourg
In ALLODD, all ESRs are actively involved in bringing the project, the objectives and results of ALLODD closer to the research community, relevant industry and public stakeholders, schools, wider public and press.
Our activities include public engagement activities for the non-scientific community, as well as the dissemination of project results through publications and presentations for the scientific community and industry.
WP5 also aims to ensure appropriate and efficient exploitation of the intellectual property emanating from the project results.
WP6: Project Management
WP Lead Beneficiary: Biomedical Research Foundation Academy of Athens
The objective of WP6 is to ensure a transparent and effective management of scientific, training, financial and administrative issues.
WP Lead Beneficiary: Biomedical Research Foundation Academy of Athens
The objective of WP6 is to ensure a transparent and effective management of scientific, training, financial and administrative issues.
|
|
This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 956314.
|
|
